Press Releases
Date picker
Category
Results per page
Kancera’s drug candidate KAND567 has a positive effect on mobility in a preclinical model of spinal cord injury
Kancera AB (Nasdaq First North Premier Growth Market: KAN) announces that an independent research group has published results showing that the company's drug candidate KAND567 has a protective effect on…
Interim report for the first quarter 2020, 1 januari-31 March 2020 Kancera AB (publ.), org.nr. 556806-8851.
First quarter in brief1 January – 31 March 2020 Net sales for the period (January to March) amounted to SEK 0,04 million (3,1). R&D costs for the period amounted to…
Kancera applies for a Phase II study with KAND567 in covid-19 patients
This is a translation of a press release in Swedish dated 2020-05-13 Kancera today announces that the company has submitted an application to the Swedish Medicines Agency for permission to…
Kancera provides an update on the development of the drug candidate KAND145
Kancera AB (Nasdaq First North Premier Growth Market: KAN) today provides an update on the development of the drug candidate KAND145. Results from the ongoing patenting process underscores the level…
Kancera reports positive results from the final part of the phase Ib program for KAND567
Kancera AB (Nasdaq First North Premier Growth Market: KAN) today announces that results from the Phase Ib program for KAND567 show that the drug candidate is well tolerated by intravenous…
Interim report for the fourth quarter 2019, 1 January – 31 December 2019 Kancera AB (publ.), org.nr. 556806-8851.
This is a translation of the report in Swedish.
Kancera has received approval to start the final part of the phase Ib program for KAND567
Kancera AB (Nasdaq First North Premier Growth Market: KAN) today announces that it has received approval from the Finnish Medicines Agency Fimea and the Ethics Committee to start the final…
Kancera reports in-depth analysis of the Phase Ib program with KAND567, showing the desired effect on the human immune system
Kancera AB (Nasdaq First North Growth Market: KAN) reports results from an in-depth immunological analysis of blood samples from healthy subjects in the ongoing Phase Ib program. The analysis shows…
Interim report for the third quarter 2019, 1 January – 30 September 2019
Third quarter in brief 1 July – 30 September 2019 Net sales for the period (January to September) amounted to SEK 3,3 Million (0,1 Million) of which the third quarter…
Kancera and partner revise the patent strategy for the HDAC project
This is a translation of a press release in Swedish published in Stockholm 2019-11-22 Kancera AB (Nasdaq First North Growth Market: KAN) and Grünenthal work together to develop HDAC inhibitors…